Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2550)	10/25/2018 5:05:53 PM
From: Miljenko Zuanic	Respond to of 3559

Model price projections per CMS: cms.gov <? CMS would phase-in the Target Price over the 5 years of the model, as a blend of ASP and the Target Price. For each calculation, if ASP is lower than the Target Price for an included drug, the model would set the payment amount to ASP for that drug. The potential phase-in would use the following blend of ASP and Target Price: Year Percentage of ASP and Target Price Year 1 80 percent ASP and 20 percent Target Price Year 2 60 percent ASP and 40 percent Target Price Year 3 40 percent ASP and 60 percent Target Price Year 4 20 percent ASP and 80 percent Target Price Year 5 100 percent Target Price ? As with current Part B drug payments, we would plan to update....>